According to two landmark studies published recently in The New England Journal of Medicine, Noxafil -- a potent new agent to prevent life-threatening IFIs -- significantly reduced the number of deaths due to fungal infections compared to other antifungals. Noxafil is the first and only antifungal approved to prevent the two most common types of IFIs. For more information on Noxafil, visit http://www.Schering-Plough.com.
SATELLITE FEEDS:
Wed, January 24th, 2007 Thurs, January 24th, 2007
6:30 PM - 6:45 PM ET 3:00 AM - 3:15 AM ET
IA 6 IA 6
Transponder 5 Transponder 5
C-Band C-Band
Downlink Freq: 3800 Vertical Downlink Freq: 3800 Vertical
Preview and access this video on Pathfire DMG: 26502 Search within the PR Newswire or MultiVu section by story ID # 26502 or by
headline For technical assistance call Pathfire Customer Care at 1-888-345-0489 or
e-mail support@pathfire.com
NEWS: Noxafil significantly reduced the number of deaths due to invasive fungal infections in high-risk patients compared to other antifungals.
FORMAT: News Package With Extra Soundbites and B-roll.
SOUNDBITES:
* John Perfect, M.D., Professor, Department of Medicine, Division of
Infectious Diseases Director, Duke University Mycology Research Unit
* Joseph Antin, M.D., Director, Adult Stem Cell Transplant Program, Dana-
Farber Cancer Institute & Professor of Medicine, Harvard Medical School
B-ROLL INCLUDES: ***Doctor/Patient Footage***Product Shots***
ADDITIONAL RESOURCES: Video, contact information and more available at
http://www.prnewswire.com/broadcast/26502/consumer.shtml
VIDEO PROVIDED BY: Schering-Plough Corporation
